IP Library Granted Patent US 8,753,650
Granted Patent B2
US 8,753,650 · App. 13/253,018 · Granted Jun 17, 2014

Patent

Inventors: Vega Masignani (Siena, IT); Marirosa Mora (Siena, IT); Maria Scarselli (Siena, IT)
Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,753,650
App. No.
13/253,018
Granted
Jun 17, 2014
Kind
B2
Abstract

The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.

Claims (7)

1. A composition comprising an isolated polypeptide comprising (a) an amino acid sequence which has at least 95% sequence identity to the amino acid sequence SEQ ID NO: 2404, or (b) a fragment of SEQ ID NO: 2404, wherein the fragment of SEQ ID NO: 2404 includes at least twenty consecutive amino acids from SEQ ID NO: 2404.

2. The composition of claim 1 , wherein the isolated polypeptide comprises (b) and the fragment includes at least fifty consecutive amino acids from SEQ ID NO: 2404.

3. The composition of claim 1 , wherein the isolated polypeptide comprises a hybrid polypeptide represented by the formula NH 2 -A-[-X-L-] n -B-COOH, wherein X is (a) or (b); L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; and n is an integer greater than 1.

4. The composition of claim 1 , further comprising an adjuvant.

5. The composition of claim 1 , wherein the composition is an immunogenic composition or a diagnostic composition.

6. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

7. The composition of claim 1 , further comprising one or more antigens selected from the group consisting of a protein antigen from Helicobacter pylori ; a protein antigen from N. meningitidis serogroup B; an outer-membrane vesicle (OMV) preparation from N. meningitidis ; a saccharide antigen from N. meningitidis serogroup A, C, W135 and/or Y; a saccharide antigen from Streptococcus pneumoniae ; an antigen from hepatitis A virus; an antigen from hepatitis B virus; an antigen from hepatitis C virus; an antigen from Bordetella pertussis ; a diphtheria antigen; a tetanus antigen; a saccharide antigen from Haemophilus influenzae B; an antigen from N. gonorrhoeae ; an antigen from Chlamydia pneumoniae ; an antigen from Streptococcus agalactiae ; an antigen from Streptococcus pyogenes ; an antigen from Chlamydia trachomatis ; an antigen from Porphyromonas gingivalis ; polio antigen(s); rabies antigen(s); measles, mumps and/or rubella antigens; influenza antigen(s); and an antigen from Moraxella catarrhalis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: MASIGNANI, VEGA; MORA, MARIROSA; SCARSELLI, MARIA
To: CHIRON S.R.L.
Reel/Frame 032397/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: NOVARTIS VACCINES & DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 032397/0890 →
CHANGE OF NAME Recorded Mar 10, 2014
From: CHIRON S.R.L.
To: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
Reel/Frame 032423/0472 →
Priority Claims (1)
GB 0107661.1 · Mar 27, 2001 · national
Continuity (3)
Division 12460422 · Jul 17, 2009
Division 10471571
Related Publication 20120020890A1 · Jan 26, 2012